Search research articles
Contact Us
Filters
Showing results (91-100 of 124) with videos related to
Page
of 13
Sort By:
Frontiers in Oncology
|
July 21, 2022
Identification and Validation of Long Non-Coding RNA LCIIAR as a Biomarker in LUAD
Wenjun Ren, Yixiao Yuan, Xi Chen, et al.
Oncology Research
|
September 8, 2025
Combining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives
Raffaele Carrano, Carlotta Zucca, Nicla Cristina, et al.
Frontiers in Oncology
|
July 1, 2021
Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
Valerio Nardone, Rocco Giannicola, Giovanna Bianco, et al.
Plos One
|
June 14, 2013
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma
Sara Busacca, Alex D Chacko, Astero Klabatsa, et al.
International Journal of Molecular Sciences
|
December 24, 2021
Evaluation of the Role of p53 Tumour Suppressor Posttranslational Modifications and TTC5 Cofactor in Lung Cancer
Hasen Alhebshi, Kun Tian, Lipsita Patnaik, et al.
Cancer Research
|
April 19, 2005
SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study
Alfonso Cristaudo, Rudy Foddis, Agnese Vivaldi, et al.
Radiation Oncology Journal
|
February 10, 2025
Reducing clinical target volume margins for multifocal glioblastoma: a multi-institutional analysis of patterns of recurrence and treatment response
Francesco Marampon, Giovanni Luca Gravina, Elisa Cinelli, et al.
Cell Death & Disease
|
October 17, 2020
Correction: P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma
Caterina Costa, Paola Indovina, Eliseo Mattioli, et al.
Cell Death & Disease
|
September 15, 2020
P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma
Caterina Costa, Paola Indovina, Eliseo Mattioli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2007
Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer
Alfonso Cristaudo, Rudy Foddis, Agnese Vivaldi, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 124) with videos related to
Sort By:
Page
of 13
Frontiers in Oncology
|
July 21, 2022
Identification and Validation of Long Non-Coding RNA LCIIAR as a Biomarker in LUAD
Wenjun Ren, Yixiao Yuan, Xi Chen, et al.
Oncology Research
|
September 8, 2025
Combining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives
Raffaele Carrano, Carlotta Zucca, Nicla Cristina, et al.
Frontiers in Oncology
|
July 1, 2021
Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
Valerio Nardone, Rocco Giannicola, Giovanna Bianco, et al.
Plos One
|
June 14, 2013
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma
Sara Busacca, Alex D Chacko, Astero Klabatsa, et al.
International Journal of Molecular Sciences
|
December 24, 2021
Evaluation of the Role of p53 Tumour Suppressor Posttranslational Modifications and TTC5 Cofactor in Lung Cancer
Hasen Alhebshi, Kun Tian, Lipsita Patnaik, et al.
Cancer Research
|
April 19, 2005
SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study
Alfonso Cristaudo, Rudy Foddis, Agnese Vivaldi, et al.
Radiation Oncology Journal
|
February 10, 2025
Reducing clinical target volume margins for multifocal glioblastoma: a multi-institutional analysis of patterns of recurrence and treatment response
Francesco Marampon, Giovanni Luca Gravina, Elisa Cinelli, et al.
Cell Death & Disease
|
October 17, 2020
Correction: P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma
Caterina Costa, Paola Indovina, Eliseo Mattioli, et al.
Cell Death & Disease
|
September 15, 2020
P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma
Caterina Costa, Paola Indovina, Eliseo Mattioli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2007
Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer
Alfonso Cristaudo, Rudy Foddis, Agnese Vivaldi, et al.
Page
of 13